Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Recommendation of “Hold” by Brokerages

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $27.00.

FLGT has been the subject of several research analyst reports. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Piper Sandler restated a “neutral” rating and set a $15.00 price target (down from $30.00) on shares of Fulgent Genetics in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th.

Institutional Investors Weigh In On Fulgent Genetics

Several large investors have recently modified their holdings of FLGT. Farther Finance Advisors LLC raised its stake in shares of Fulgent Genetics by 69.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after purchasing an additional 548 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Fulgent Genetics during the fourth quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Fulgent Genetics by 214.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock worth $48,000 after purchasing an additional 1,251 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Fulgent Genetics during the second quarter worth approximately $49,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in shares of Fulgent Genetics during the fourth quarter worth approximately $56,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

FLGT stock opened at $17.11 on Monday. The company has a market capitalization of $509.02 million, a P/E ratio of -7.16 and a beta of 0.88. Fulgent Genetics has a twelve month low of $13.46 and a twelve month high of $31.04. The business has a 50 day simple moving average of $15.82 and a 200-day simple moving average of $22.11.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.14. The business had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative return on equity of 3.24% and a negative net margin of 23.04%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Research analysts predict that Fulgent Genetics will post -2.81 EPS for the current fiscal year.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.